[go: up one dir, main page]

WO2013070981A3 - Treating er stress related disorders by stabilizing intracellular calcium homeostasis - Google Patents

Treating er stress related disorders by stabilizing intracellular calcium homeostasis Download PDF

Info

Publication number
WO2013070981A3
WO2013070981A3 PCT/US2012/064244 US2012064244W WO2013070981A3 WO 2013070981 A3 WO2013070981 A3 WO 2013070981A3 US 2012064244 W US2012064244 W US 2012064244W WO 2013070981 A3 WO2013070981 A3 WO 2013070981A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
related disorders
calcium homeostasis
intracellular calcium
stress related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/064244
Other languages
French (fr)
Other versions
WO2013070981A2 (en
Inventor
Sic L. CHAN
Cherine BELAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Central Florida Research Foundation Inc
Original Assignee
University of Central Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Central Florida Research Foundation Inc filed Critical University of Central Florida Research Foundation Inc
Publication of WO2013070981A2 publication Critical patent/WO2013070981A2/en
Publication of WO2013070981A3 publication Critical patent/WO2013070981A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed herein are methods of treating and preventing neurodegenerative disorders associated with calcium imbalances in neural cells. Provided are compositions that serve to stabilize calcium homeostasis. Particularly exemplified is the administration of salubrinal for a subject in need of treatment.
PCT/US2012/064244 2011-11-08 2012-11-08 Treating er stress related disorders by stabilizing intracellular calcium homeostasis Ceased WO2013070981A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161556932P 2011-11-08 2011-11-08
US61/556,932 2011-11-08

Publications (2)

Publication Number Publication Date
WO2013070981A2 WO2013070981A2 (en) 2013-05-16
WO2013070981A3 true WO2013070981A3 (en) 2013-07-11

Family

ID=48290764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/064244 Ceased WO2013070981A2 (en) 2011-11-08 2012-11-08 Treating er stress related disorders by stabilizing intracellular calcium homeostasis

Country Status (1)

Country Link
WO (1) WO2013070981A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441574B2 (en) 2014-11-13 2019-10-15 Washington University Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
CN115350188A (en) * 2022-07-25 2022-11-18 福建医科大学附属第一医院 Application of small molecular compound Salubrinal in the preparation of medicines for treating or improving sarcopenia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255485A1 (en) * 2007-11-28 2010-10-07 Pico Caroni Biomarkers for the onset of neurodegenerative diseases
US20100261753A1 (en) * 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system
WO2011017030A2 (en) * 2009-08-06 2011-02-10 Neuraltus Pharmaceuticals, Inc. Treatment of macrophage-related disorders
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
US20100255485A1 (en) * 2007-11-28 2010-10-07 Pico Caroni Biomarkers for the onset of neurodegenerative diseases
US20100261753A1 (en) * 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system
WO2011017030A2 (en) * 2009-08-06 2011-02-10 Neuraltus Pharmaceuticals, Inc. Treatment of macrophage-related disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANDOPADHYAY, R. ET AL.: "Pathogenesis of Parkinson' s disease:emerging role of molecular chaperones", TRENDS IN MOLECULAR MEDICINE, vol. 16, no. 1, 23 December 2009 (2009-12-23), pages 27 - 36, XP026835313 *
BELAL, C. ET AL.: "The homocysteine-inducible endoplasmic reticulum (ER) stress protein Herp counteracts mutant a-synuclein-induced ER stress via the homeostatic regulation of ER-resident calcium release channel proteins", HUMAN MOLECULAR GENETICS, 20 December 2011 (2011-12-20), pages 1 - 15, XP055081116 *
SMITH, W. W. ET AL.: "Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity", HUMAN MOLECULEAR GENETICS, vol. 14, no. 24, 20 October 2005 (2005-10-20), pages 3801 - 3811, XP055077314 *

Also Published As

Publication number Publication date
WO2013070981A2 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
IL274469A (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
MY170802A (en) Treatment of pulmonary disease
WO2012114204A3 (en) Methods of treating mitochondrial dysfunction
WO2013061161A3 (en) New combination therapies for treating neurological disorders
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
HK1210599A1 (en) Abuse deterrent pharmaceutical compositions for controlled release
WO2011083150A3 (en) Obesity small molecules
IL239565B (en) Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2013012915A9 (en) Heterocyclic compounds and uses thereof
EA201391615A1 (en) DATED POTENTIATORS CFTR
PH12013500577A1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX362185B (en) Compositions and treatment for eye diseases and disorders.
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
HK1197159A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
IL232710A0 (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
WO2012170945A3 (en) Methods for modulating kallikrein (klkb1) expression
HK1199261A1 (en) Methods for treatment of diseases
MX2017004658A (en) Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder.
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MY171048A (en) Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions
HK1216095A1 (en) New positive allosteric modulators of nicotinic acetylcholine receptor
HK1213175A1 (en) Treatment and/or prophylaxis of tspo mediated diseases and/or disorders
BR112014004737A2 (en) Ambroxol Hydrochloride Compound Compound and Method of Preparation of Compound
WO2013070981A3 (en) Treating er stress related disorders by stabilizing intracellular calcium homeostasis

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 12848015

Country of ref document: EP

Kind code of ref document: A2